The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Witthuhn, B. A., Quelle, F. W., Silvennoinen, O., Yi, T., Tang, B., Miura, O., & Ihle, J. N. (1993) · Cell · doi:10.1016/0092-8674(93)90414-l · Cited by 1,194
A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia
Lacronique, V., Boureux, A., Della Valle, V., Poirel, H., Quang, C. T., Mauchauffé, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997) · Science · doi:10.1126/science.278.5341.1309 · Cited by 791
Self-citationPolycythemia vera: myths, mechanisms, and management
Spivak, J. L. (2002) · Blood · doi:10.1182/blood-2001-12-0349 · Cited by 463
Bone-Marrow Responses in Polycythemia Vera
(1974) · New England Journal of Medicine · doi:10.1056/nejm197406132902419 · Cited by 420
Dumoutier, L., Van Roost, E., Colau, D., & Renauld, J.-C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170291697 · Cited by 365
Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain
Saharinen, P., Takaluoma, K., & Silvennoinen, O. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.10.3387-3395.2000 · Cited by 365
Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera
Kralovics, R., Guan, Y., & Prchal, J. T. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00789-5 · Cited by 300
Huang, L. J.-S., Constantinescu, S. N., & Lodish, H. F. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00401-4 · Cited by 294
Self-citationMutation in the Jak Kinase JH2 Domain Hyperactivates Drosophila and Mammalian Jak-Stat Pathways
Luo, H., Rose, P., Barber, D., Hanratty, W. P., Lee, S., Roberts, T. M., D’Andrea, A. D., & Dearolf, C. R. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1562 · Cited by 242
A JAK1/JAK2 Chimera Can Sustain Alpha and Gamma Interferon Responses
Kohlhuber, F. K., Rogers, N. C., Watling, D., Feng, J., Guschin, D., Briscoe, J., Witthuhn, B. A., Kotenko, S. V., Pestka, S., Stark, G. R., et al. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.2.695 · Cited by 218
Cited by
Items 101–189 of 189
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
Tefferi, A., Lasho, T. L., Guglielmelli, P., Finke, C. M., Rotunno, G., Elala, Y., Pacilli, A., Hanson, C. A., Pancrazzi, A., Ketterling, R. P., et al. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000216 · Cited by 311
Cytokine receptor signaling through the Jak–Stat–Socs pathway in disease
O'Sullivan, L. A., Liongue, C., Lewis, R. S., Stephenson, S. E. M., & Ward, A. C. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.11.025 · Cited by 308
Hercus, T. R., Thomas, D., Guthridge, M. A., Ekert, P. G., King-Scott, J., Parker, M. W., & Lopez, A. F. (2009) · Blood · doi:10.1182/blood-2008-12-164004 · Cited by 307
Current and future status of JAK inhibitors
McLornan, D. P., Pope, J. E., Gotlib, J., & Harrison, C. N. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00438-4 · Cited by 305
Molecular biomarkers in acute myeloid leukemia
Prada-Arismendy, J., Arroyave, J. C., & Röthlisberger, S. (2017) · Blood Reviews · doi:10.1016/j.blre.2016.08.005 · Cited by 304
Wolanskyj, A. P., Lasho, T. L., Schwager, S. M., McClure, R. F., Wadleigh, M., Lee, S. J., Gary Gilliland, D., & Tefferi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05764.x · Cited by 303
Pietra, D., Rumi, E., Ferretti, V. V., Buduo, C. A. D., Milanesi, C., Cavalloni, C., Sant'Antonio, E., Abbonante, V, Moccia, F., Casetti, I. C., et al. (2016) · Leukemia · doi:10.1038/leu.2015.277 · Cited by 303
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 302
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
Rampal, R., Ahn, J., Abdel-Wahab, O., Nahas, M., Wang, K., Lipson, D., Otto, G. A., Yelensky, R., Hricik, T., McKenney, A. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407792111 · Cited by 301
Kershaw, N. J., Murphy, J. M., Liau, N. P. D., Varghese, L. N., Laktyushin, A., Whitlock, E. L., Lucet, I. S., Nicola, N. A., & Babon, J. J. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2519 · Cited by 301
Pietra, D., Li, S., Brisci, A., Passamonti, F., Rumi, E., Theocharides, A., Ferrari, M., Gisslinger, H., Kralovics, R., Cremonesi, L., et al. (2008) · Blood · doi:10.1182/blood-2007-07-101576 · Cited by 298
Campbell, P. J., Baxter, E. J., Beer, P. A., Scott, L. M., Bench, A. J., Huntly, B. J. P., Erber, W. N., Kusec, R., Larsen, T. S., Giraudier, S., et al. (2006) · Blood · doi:10.1182/blood-2005-12-013748 · Cited by 298
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Pardanani, A., & Tefferi, A. (2008) · Leukemia · doi:10.1038/leu.2008.113 · Cited by 294
Scott, L. M., Scott, M. A., Campbell, P. J., & Green, A. R. (2006) · Blood · doi:10.1182/blood-2006-04-018259 · Cited by 294
Liu, B. A., Jablonowski, K., Raina, M., Arcé, M., Pawson, T., & Nash, P. D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.001 · Cited by 294
Elf, S., Abdelfattah, N. S., Chen, E., Perales-Patón, J., Rosen, E. A., Ko, A., Peisker, F., Florescu, N., Giannini, S., Wolach, O., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1434 · Cited by 293
Canonical and non-canonical JAK–STAT signaling
Li, W. X. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.08.008 · Cited by 290
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Quintás-Cardama, A., Kantarjian, H., Cortes, J., & Verstovsek, S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3264 · Cited by 290
Pathogenesis of Myelofibrosis With Myeloid Metaplasia
Tefferi, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.9316 · Cited by 289
Jamieson, C. H. M., Gotlib, J., Durocher, J. A., Chao, M. P., Mariappan, M. R., Lay, M., Jones, C., Zehnder, J. L., Lilleberg, S. L., & Weissman, I. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601462103 · Cited by 286
Milosevic Feenstra, J. D., Nivarthi, H., Gisslinger, H., Leroy, E., Rumi, E., Chachoua, I., Bagienski, K., Kubesova, B., Pietra, D., Gisslinger, B., et al. (2016) · Blood · doi:10.1182/blood-2015-07-661835 · Cited by 284
Self-citationMolecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
Quintás-Cardama, A., & Verstovsek, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0284 · Cited by 284
Babon, J. J., Kershaw, N. J., Murphy, J. M., Varghese, L. N., Laktyushin, A., Young, S. N., Lucet, I. S., Norton, R. S., & Nicola, N. A. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.015 · Cited by 279
Levine, R. L., & Gilliland, D. G. (2008) · Blood · doi:10.1182/blood-2008-03-077966 · Cited by 279
Kralovics, R., Teo, S.-S., Li, S., Theocharides, A., Buser, A. S., Tichelli, A., & Skoda, R. C. (2006) · Blood · doi:10.1182/blood-2005-11-009605 · Cited by 278
Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd–Chiari Syndrome
Patel, R. K., Lea, N. C., Heneghan, M. A., Westwood, N. B., Milojkovic, D., Thanigaikumar, M., Yallop, D., Arya, R., Pagliuca, A., Gäken, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.008 · Cited by 277
Ungureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O. N., Xu, C.-F., Neubert, T. A., Skoda, R. C., Hubbard, S. R., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2099 · Cited by 276
A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties
Murphy, J. M., Zhang, Q., Young, S. N., Reese, M. L., Bailey, F. P., Eyers, P. A., Ungureanu, D., Hammaren, H., Silvennoinen, O., Varghese, L. N., et al. (2014) · Biochemical Journal · doi:10.1042/bj20131174 · Cited by 276
Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
Koo, G. C., Tan, S. Y., Tang, T., Poon, S. L., Allen, G. E., Tan, L., Chong, S. C., Ong, W. S., Tay, K., Tao, M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0028 · Cited by 275
Targeting TGF-β signaling for the treatment of fibrosis
Györfi, A. H., Matei, A.-E., & Distler, J. H. W. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.016 · Cited by 274
Liu, F., Zhao, X., Perna, F., Wang, L., Koppikar, P., Abdel-Wahab, O., Harr, M. W., Levine, R. L., Xu, H., Tefferi, A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.020 · Cited by 273
Williams, N. K., Bamert, R. S., Patel, O., Wang, C., Walden, P. M., Wilks, A. F., Fantino, E., Rossjohn, J., & Lucet, I. S. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.01.041 · Cited by 270
Hultcrantz, M., Björkholm, M., Dickman, P. W., Landgren, O., Derolf, Å. R., Kristinsson, S. Y., & Andersson, T. M. L. (2018) · Annals of Internal Medicine · doi:10.7326/m17-0028 · Cited by 268
Wilkins, B. S., Erber, W. N., Bareford, D., Buck, G., Wheatley, K., East, C. L., Paul, B., Harrison, C. N., Green, A. R., & Campbell, P. J. (2008) · Blood · doi:10.1182/blood-2007-05-091850 · Cited by 268
Hinds, D. A., Barnholt, K. E., Mesa, R. A., Kiefer, A. K., Do, C. B., Eriksson, N., Mountain, J. L., Francke, U., Tung, J. Y., Nguyen, H. (., et al. (2016) · Blood · doi:10.1182/blood-2015-06-652941 · Cited by 267
“V617F gene dosage also contributes to phenotype; V617F allele burden tends to be higher in PV and PMF because of acquired uniparental disomy (UPD), whereas a lower allele burden is generally observed in ET patients.(1-5) Mutations in exon 12 of JAK2 in PV,(6) in the thrombopoietin (TPO) receptor MPL in ET and PMF,(7,8…”
BackgroundLucet, I. S., Fantino, E., Styles, M., Bamert, R., Patel, O., Broughton, S. E., Walter, M., Burns, C. J., Treutlein, H., Wilks, A. F., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2413 · Cited by 266
Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 V617F Mice
Wang, W., Liu, W., Fidler, T., Wang, Y., Tang, Y., Woods, B., Welch, C., Cai, B., Silvestre-Roig, C., Ai, D., et al. (2018) · Circulation Research · doi:10.1161/circresaha.118.313283 · Cited by 262
EZH2 mutational status predicts poor survival in myelofibrosis
Guglielmelli, P., Biamonte, F., Score, J., Hidalgo-Curtis, C., Cervantes, F., Maffioli, M., Fanelli, T., Ernst, T., Winkelman, N., Jones, A. V., et al. (2011) · Blood · doi:10.1182/blood-2011-06-363424 · Cited by 262
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Tefferi, A., Lasho, T. L., Jimma, T., Finke, C. M., Gangat, N., Vaidya, R., Begna, K. H., Al-Kali, A., Ketterling, R. P., Hanson, C. A., et al. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.11.001 · Cited by 260
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms
Rumi, E., & Cazzola, M. (2017) · Blood · doi:10.1182/blood-2016-10-695957 · Cited by 258
Barosi, G., Bergamaschi, G., Marchetti, M., Vannucchi, A. M., Guglielmelli, P., Antonioli, E., Massa, M., Rosti, V., Campanelli, R., Villani, L., et al. (2007) · Blood · doi:10.1182/blood-2007-07-099184 · Cited by 258
Hematopoietic cytokine receptor signaling
Baker, S. J., Rane, S. G., & Reddy, E. P. (2007) · Oncogene · doi:10.1038/sj.onc.1210757 · Cited by 256
“…of the JH2 domain in the regulation of JAK activity has been recently underscored in patients suffering from myeloproliferative disorders, in particular, those whose cells express the mutant JAK2V617F protein (Baxter et al., 2005; James et al., 2005; Kralovics et al., 2005; Levine et al., 2005).”
BackgroundPrimignani, M., Barosi, G., Bergamaschi, G., Gianelli, U., Fabris, F., Reati, R., Dell'Era, A., Bucciarelli, P., & Mannucci, P. M. (2006) · Hepatology · doi:10.1002/hep.21435 · Cited by 254
Passamonti, F., Rumi, E., Pietra, D., Porta, M. G. D., Boveri, E., Pascutto, C., Vanelli, L., Arcaini, L., Burcheri, S., Malcovati, L., et al. (2006) · Blood · doi:10.1182/blood-2005-09-3826 · Cited by 253
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Tefferi, A., Cortes, J., Verstovsek, S., Mesa, R. A., Thomas, D., Lasho, T. L., Hogan, W. J., Litzow, M. R., Allred, J. B., Jones, D., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004572 · Cited by 253
Hexner, E. O., Serdikoff, C., Jan, M., Swider, C. R., Robinson, C., Yang, S., Angeles, T., Emerson, S. G., Carroll, M., Ruggeri, B., et al. (2008) · Blood · doi:10.1182/blood-2007-04-083402 · Cited by 252
Ba/F3 cells and their use in kinase drug discovery
Warmuth, M., Kim, S., Gu, X.-J., Xia, G., & Adrián, F. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328011a25f · Cited by 240
Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia
Ramos, P., Casu, C., Gardenghi, S., Breda, L., Crielaard, B. J., Guy, E., Marongiu, M. F., Gupta, R., Levine, R. L., Abdel-Wahab, O., et al. (2013) · Nature Medicine · doi:10.1038/nm.3126 · Cited by 227
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis
Campbell, P. J. (2006) · Blood · doi:10.1182/blood-2005-08-3395 · Cited by 224
“(2) Department of Internal Medicine III, University of Ulm, Ulm, Germany.”
BackgroundPivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis
Ciurea, S. O., Merchant, D., Mahmud, N., Ishii, T., Zhao, Y., Hu, W., Bruno, E., Barosi, G., Xu, M., & Hoffman, R. (2007) · Blood · doi:10.1182/blood-2006-12-064626 · Cited by 213
Van Egeren, D., Escabi, J., Nguyen, M., Liu, S., Reilly, C. R., Patel, S., Kamaz, B., Kalyva, M., DeAngelo, D. J., Galinsky, I., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.02.001 · Cited by 206
Psaila, B., Wang, G., Rodriguez-Meira, A., Li, R., Heuston, E. F., Murphy, L., Yee, D., Hitchcock, I. S., Sousos, N., O’Sullivan, J., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.008 · Cited by 185
The HIF pathway and erythrocytosis
Lee, F. S., & Percy, M. J. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130321 · Cited by 177
Dentali, F., Squizzato, A., Brivio, L., Appio, L., Campiotti, L., Crowther, M., Grandi, A. M., & Ageno, W. (2009) · Blood · doi:10.1182/blood-2008-12-196014 · Cited by 176
Shi, J. G., Chen, X., McGee, R. F., Landman, R. R., Emm, T., Lo, Y., Scherle, P. A., Punwani, N. G., Williams, W. V., & Yeleswaram, S. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010389469 · Cited by 168
Scott, L. M., Campbell, P. J., Baxter, E. J., Todd, T., Stephens, P., Edkins, S., Wooster, R., Stratton, M. R., Futreal, P. A., & Green, A. R. (2005) · Blood · doi:10.1182/blood-2005-05-2087 · Cited by 158
Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera
Casu, C., Oikonomidou, P. R., Chen, H., Nandi, V., Ginzburg, Y., Prasad, P., Fleming, R. E., Shah, Y. M., Valore, E. V., Nemeth, E., et al. (2016) · Blood · doi:10.1182/blood-2015-10-676742 · Cited by 148
Portal vein thrombosis, revisited
Primignani, M. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.08.003 · Cited by 146
Gallardo, M., Lee, H. J., Zhang, X., Bueso-Ramos, C., Pageon, L. R., McArthur, M., Multani, A., Nazha, A., Manshouri, T., Parker-Thornburg, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.001 · Cited by 145
Myeloid malignancies: mutations, models and management
Murati, A., Brecqueville, M., Devillier, R., Mozziconacci, M.-J., Gelsi-Boyer, V., & Birnbaum, D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-304 · Cited by 139
JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation
Edelmann, B., Gupta, N., Schnoeder, T. M., Oelschlegel, A. M., Shahzad, K., Goldschmidt, J., Philipsen, L., Weinert, S., Ghosh, A., Saalfeld, F. C., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci90312 · Cited by 138
Inflammation and myeloproliferative neoplasms
Lussana, F., & Rambaldi, A. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.06.010 · Cited by 136
Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications
Pourcelot, E., Trocme, C., Mondet, J., Bailly, S., Toussaint, B., & Mossuz, P. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.01.006 · Cited by 132
Clonal Hematopoiesis: Mechanisms Driving Dominance of Stem Cell Clones
Challen, G., & Goodell, M. A. (2020) · Blood · doi:10.1182/blood.2020006510 · Cited by 131
Janus kinase deregulation in leukemia and lymphoma
Chen, E., Staudt, L. M., & Green, A. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.017 · Cited by 123
“Mutations of JAK family members recently came to prominence with the discovery of the V617F mutation in JAK2 in a substantial proportion of patients with chronic myeloproliferative neoplasms (MPNs) (Baxter et al., 2005; James et al., 2005; Kralovics et al., 2005; Levine et al., 2005b).”
The role of apoptosis in megakaryocytes and platelets
Kile, B. T. (2014) · British Journal of Haematology · doi:10.1111/bjh.12757 · Cited by 122
Fetal lung and placental methylation is associated with in utero nicotine exposure
Chhabra, D., Sharma, S., Kho, A. T., Gaedigk, R., Vyhlidal, C. A., Leeder, J. S., Morrow, J., Carey, V. J., Weiss, S. T., Tantisira, K. G., et al. (2014) · Epigenetics · doi:10.4161/15592294.2014.971593 · Cited by 102
Jacquelin, S., Straube, J., Cooper, L., Vu, T., Song, A., Bywater, M., Baxter, E., Heidecker, M., Wackrow, B., Porter, A., et al. (2018) · Blood · doi:10.1182/blood-2018-04-846220 · Cited by 99
Canté-Barrett, K., Spijkers-Hagelstein, J. A. P., Buijs-Gladdines, J. G. C. A. M., Uitdehaag, J. C. M., Smits, W. K., van der Zwet, J., Buijsman, R. C., Zaman, G. J. R., Pieters, R., & Meijerink, J. P. P. (2016) · Leukemia · doi:10.1038/leu.2016.83 · Cited by 94
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
AKT is a therapeutic target in myeloproliferative neoplasms
Khan, I., Huang, Z., Wen, Q., Stankiewicz, M. J., Gilles, L., Goldenson, B., Schultz, R., Diebold, L., Gurbuxani, S., Finke, C. M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.167 · Cited by 74
Phospho‐STAT5 and phospho‐Akt expression in chronic myeloproliferative neoplasms
Grimwade, L. F., Happerfield, L., Tristram, C., McIntosh, G., Rees, M., Bench, A. J., Boyd, E. M., Hall, M., Quinn, A., Piggott, N., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07870.x · Cited by 69
Clonal hematopoiesis and hematological malignancy
Dunn, W. G., McLoughlin, M. A., & Vassiliou, G. S. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180065 · Cited by 61
Austin, R. J., Straube, J., Bruedigam, C., Pali, G., Jacquelin, S., Vu, T., Green, J., Gräsel, J., Lansink, L., Cooper, L., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0638-y · Cited by 61
Mosca, M., Hermange, G., Tisserand, A., Noble, R., Marzac, C., Marty, C., Le Sueur, C., Campario, H., Vertenoeil, G., El-Khoury, M., et al. (2021) · Blood · doi:10.1182/blood.2021010986 · Cited by 57
Self-citationJAK-STAT Signaling in Stem Cells
Stine, R. R., & Matunis, E. L. (2013) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-007-6621-1_14 · Cited by 56
Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
Cacemiro, M. D. C., Cominal, J. G., Tognon, R., Nunes, N. D. S., Simões, B. P., Figueiredo-Pontes, L. L. D., Catto, L. F. B., Traina, F., Souto, E. X., Zambuzi, F. A., et al. (2018) · Hematology, Transfusion and Cell Therapy · doi:10.1016/j.htct.2017.12.003 · Cited by 55
The use of structural biology in Janus kinase targeted drug discovery
L. Alicea-Velazquez, N., & J. Boggon, T. (2011) · Current Drug Targets · doi:10.2174/138945011794751528 · Cited by 53
Grabek, J., Straube, J., Bywater, M., & Lane, S. W. (2020) · Cells · doi:10.3390/cells9081901 · Cited by 53
JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation
Oku, S., Takenaka, K., Kuriyama, T., Shide, K., Kumano, T., Kikushige, Y., Urata, S., Yamauchi, T., Iwamoto, C., Shimoda, H. K., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08249.x · Cited by 51
Al-Sheikh, M., Moradkhani, K., Lopez, M., Wajcman, H., & Préhu, C. (2008) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.07.017 · Cited by 50
Rationale for Targeting the PI3K/Akt/mTOR Pathway in Myeloproliferative Neoplasms
Bartalucci, N., Guglielmelli, P., & Vannucchi, A. M. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.07.011 · Cited by 49
Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera
Tsuruta-Kishino, T., Koya, J., Kataoka, K., Narukawa, K., Sumitomo, Y., Kobayashi, H., Sato, T., & Kurokawa, M. (2017) · Oncogene · doi:10.1038/onc.2016.478 · Cited by 41
Laubach, J. P., Fu, P., Jiang, X., Salter, K. H., Potti, A., & Arcasoy, M. O. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.09.009 · Cited by 41
Shepherd, M. S., Li, J., Wilson, N. K., Oedekoven, C. A., Li, J., Belmonte, M., Fink, J., Prick, J. C. M., Pask, D. C., Hamilton, T. L., et al. (2018) · Blood · doi:10.1182/blood-2017-12-821066 · Cited by 33
Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN
Schnöder, T. M., Eberhardt, J., Koehler, M., Bierhoff, H. B., Weinert, S., Pandey, A. D., Nimmagadda, S. C., Wolleschak, D., Jöhrens, K., Fischer, T., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2354-1 · Cited by 13
Investigational Janus kinase inhibitors in development for myelofibrosis
Bose, P., Abou Zahr, A., & Verstovsek, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1323871 · Cited by 12
Steensma, D. P., & Pardanani, A. (2006) · Blood · doi:10.1182/blood-2005-09-3646 · Cited by 10
Metadata
- Authors
- James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J. L., Constantinescu, S. N., Casadevall, N., & Vainchenker, W.
- Venue
- Nature
- Published
- 2005-03-27
- Volume
- 434
- Issue
- 7037
- Pages
- 1144-1148
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2049145190
- Cited by
- 3,544
- References
- 28
- FWCI
- 106.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.